No Picture
Trading Ideas

Was The Smart Money Smart About Dave & Buster’s Entertainment (PLAY)?

Hedge funds don’t get the respect they used to get. Nowadays investors prefer passive funds over actively managed funds. One thing they don’t realize is that 100% of the passive funds didn’t see the coronavirus recession coming, but a lot of hedge funds did. Even we published an article near the end of February and […] …read more […]

No Picture
Trading Ideas

Trump asking justices to bar demands for taxes, bank records

President Donald Trump is hoping to persuade a Supreme Court with two of his appointees to keep his tax and other financial records from being turned over to lawmakers and a New York district attorney. The justices are hearing arguments by telephone Tuesday in a pivotal legal fight that could affect the presidential campaign, even with the coronavirus outbreak and the resulting economic fallout. Rulings against the president could result in the quick release of personal financial information that Trump has sought strenuously to keep private. …read more […]

No Picture
Trading Ideas

3 “Strong Buy” Penny Stocks with Massive Upside Ahead

Stocks are on the rise, but why? The glum results of earnings season have not caused another panic – rather, investors seem to be taking them in stride as ‘baked in’ to the current financial situation. The indexes are generally holding steady, at resistance levels Wall Street had predicted two weeks ago. And this brings up the questions, How long will this last? and What will happen next? Weighing in from Morgan Stanley, chief US equity strategist Michael Wilson believes that stocks hit their true bottom on March 23. In his view, the coronavirus and the collapse in oil markets …read more […]

No Picture
Trading Ideas

AstraZeneca-Merck Ovarian Cancer Treatment Gets FDA Approval

The U.S. Food and Drug Administration (FDA) approved a treatment developed by AstraZeneca (AZN) and Merck Co. (MRK) for advanced ovarian cancer.The FDA approved the ovarian drug Lynparza to be used in combination with bevacizumab as a first-line maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer. Patients will be selected for therapy based on an FDA-approved companion diagnostic for Lynparza.Lynparza is a first-in-class PARP inhibitor, which is a targeted treatment to potentially exploit DNA damage response (DDR) pathway deficiencies, such as so-called BRCA mutations to kill cancer cells. It is being tested in …read more […]